INVITED REVIEW

G protein mutations in endocrine diseases

Andrea Lania, Giovanna Mantovani and Anna Spada

Institute of Endocrine Sciences, Ospedale Maggiore IRCCS, University of Milan, Via F. Sforza 35, 20122 Milano, Italy

(Correspondence should be addressed to A. Spada, Istituto di Scienze Endocrine, Pad. Graneli, Ospedale Maggiore IRCCS, Via Francesco Sforza 35, 20122 Milano, Italy; Email: anna.spada@unimi.it)

Abstract

This review summarizes the pathogenetic role of naturally occurring mutations of G protein genes in endocrine diseases. Although *in vitro* mutagenesis and transfection assays indicate that several G proteins have mitogenic potential, to date only two G proteins have been identified which harbor naturally occurring mutations, Gs α , the activator of adenylyl cyclase and Gi2 α , which is involved in several functions, including adenylyl cyclase inhibition and ion channel modulation. The gene encoding Gs α (GNAS1) may be altered by loss or gain of function mutations. Indeed, heterozygous inactivating germ line mutations in this gene cause pseudohypoparathyroidism type Ia, in which physical features of Albright hereditary osteodystrophy (AHO) are associated with resistance to several hormones, i.e. PTH, TSH and gonadotropins, that activate Gs-coupled receptors or pseudopseudohypoparathyroidism in which AHO is the only clinical manifestation. Evidence suggests that the variable and tissue-specific hormone resistance observed in PHP Ia may result from tissue-specific imprinting of the GNAS1 gene, although the Gs α knockout model only in part reproduces the human AHO phenotype. Activating somatic Gs α mutations leading to cell proliferation have been identified in endocrine tumors constituted by cells in which cAMP is a mitogenic signal, i.e. GH-secreting pituitary adenomas, hyperfunctioning thyroid adenomas and Leydig cell tumors. When the same mutations occur very early in embryogenesis they cause McCune–Albright syndrome. Although these mutations would in principle confer growth advantage, studies failed to detect differences in the clinical and hormonal phenotypes, suggesting the existence of mechanisms able to counteract the activation of the cAMP pathway. Activating mutations of Gi2 α have been identified in a subset of ovarian, adrenal and pituitary tumors, but their prevalence and significance are still controversial. Finally, although G α subunits are the only components of the heterotrimeric GTP binding proteins which harbor known mutations, β/γ subunits should be considered possible targets of genetic alterations as suggested by the frequent presence of $\beta 3$ subunit variants in patients with essential hypertension.

European Journal of Endocrinology 145 543–559

Introduction

The majority of polypeptide hormones, all monoamine neurotransmitters, prostaglandins and even ions, such as Ca²⁺, signal their target cells through membrane receptors belonging to a superfamily that share a common structural and functional motif, i.e. a single polypeptide with seven membrane-spanning domains, and a common transduction mechanism, i.e. coupling to G proteins. Therefore, G proteins play a key role in relaying signals from the plasma membrane to intracellular effectors. In the past few years, defects in G protein-coupled signal transduction have been identified as the cause of endocrine disorders (1–6). In particular, several G protein-coupled receptors have been demonstrated to be altered by loss or gain of function mutations, leading to the clinical phenotype of hormone defect or excess, respectively. Conversely,

while a number of mutant G proteins cause cell transformation, as demonstrated by *in vitro* mutagenesis and transfection assays, to date only two G protein genes have been identified which harbor naturally occurring mutations in endocrine disorders. Moreover, mutations of the effector molecules seem to occur even more infrequently in human diseases. This review will briefly describe how G proteins activate signal transduction and how mutations of these proteins cause endocrine diseases.

G protein structure and function

Heterotrimeric guanine nucleotide binding proteins, known as G proteins, form the superfamily of proteins involved in the signal transduction from seven transmembrane receptors to intracellular effectors. They are

heterotrimers composed of three distinct subunits, α , β and γ , the functional specificity of each G protein depending on the α subunit, which differs from one G protein to another (7–9). The α subunit contains high affinity binding sites for guanine nucleotide and has intrinsic GTPase activity. The α subunit guanine nucleotide pocket consists of five distinct, highly conserved stretches (G1–G5). The G1, G4 and G5 regions are important for the binding of GTP while the G2 and G3 regions determine the intrinsic GTPase activity of the α subunit. The GDP-bound form binds tightly to $\beta\gamma$ and is inactive, whereas the GTP-bound form dissociates from $\beta\gamma$ and serves as a regulator of effector proteins. The receptor molecules cause the activation of G proteins by affecting several steps of the GTP cycle, resulting in the facilitation of the exchange

of GTP for GDP on the α subunit. The duration of subunit separation is timed by the rate of α subunit mediated hydrolysis of GTP (Fig. 1). However, deactivation of G protein signaling pathways *in vivo* can occur 10- to 100-fold faster than the rate of GTP hydrolysis *in vitro*, suggesting the existence of GTPase activating proteins able to deactivate the α subunit. In fact, a family of GTPase activating proteins termed RGS (regulators of G protein signaling), that deactivates several G proteins by allowing inactive heterotrimers to reform, has been identified (10–12). It is worth noting that a RGS protein able to deactivate the stimulatory regulatory protein of adenylyl cyclase has not yet been identified (12).

Although the $G\alpha$ subunit family includes proteins with different functions, unequivocal assignment of one

Receptor activation

Figure 1 Schematic representation of G protein activation and signaling. Heterotrimeric G proteins are composed of three distinct subunits α , β and γ , the functional specificity of each G protein depending on the α subunit. The α subunit contains high affinity binding sites for guanine nucleotides and has intrinsic GTPase activity. The GDP-bound form binds tightly to $\beta\gamma$ and is inactive, whereas the GTP-bound form dissociates from $\beta\gamma$ and serves as a regulator of effector proteins. The receptor molecules cause the activation of G proteins by facilitating the exchange of GTP for GDP on the α subunit. The duration of subunit separation is timed by the rate of α subunit mediated hydrolysis of GTP. Finally, a family of GTPase activating proteins termed RGS (regulators of G protein signaling) are able to deactivate several G proteins by allowing inactive heterotrimers to reform.

Table 1 G protein signaling.

G α subtype	Downstream signal
Gs α	Increased AC activity Ca ²⁺ L-channel opening K ⁺ -channel closing
Gi ₁₋₃ α , Go α	Reduced AC activity Ca ²⁺ L-channel closing K ⁺ -channel opening
Gq/11 α	Increased PLC β activity
G ₁₃ α	Cytoskeleton rearrangement Na ⁺ /H ⁺ antiporter

AC, adenylyl cyclase; PLC β , phospholipase C β .

G protein to a single effector molecule has been only achieved for some G proteins (13–15). To date, about 20 distinct α subunits have been cloned. According to homologies in sequence and function, they can be divided into four major subfamilies represented by Gs α , Gi α , Gq α and G12 α . Proteins of the Gs class have been defined as ubiquitous activators of all adenylyl cyclase isoforms, whereas their effects on ion channel activity are restricted to selected cell types. Members of the Gi class, which includes several protein substrates for pertussis toxin ADP ribosylation such as Gi1–3 and Go, are involved in adenylyl cyclase inhibition, ion channel modulation and phosphatase activation. Subunits of the Gq/11 class are putative mediators of phospholipase C activation, whereas the current knowledge about G α 12, 13 and Z is sparse (Table 1).

Five β subunits and 12 γ subunits have so far been identified. Until recently the G protein α subunit alone was thought to activate intracellular effectors, newer evidence indicates that β and/or γ subunits also play a part in signal transduction. In fact, it has been demonstrated that these subunits may activate specific isoforms of both phospholipase C and adenylyl cyclase (16). This additional mechanism of action of G proteins seems to occur with high selectivity. For instance,

whereas $\beta\gamma$ inhibits type I adenylyl cyclase activity, this complex greatly potentiates the stimulatory effect of Gs on both type II and IV adenylyl cyclase and is ineffective on the other isoforms (17, 18). Moreover, among the different β and γ subunits so far cloned, the $\beta\gamma$ of the Gi family seems to be frequently involved in the modulation of intracellular effectors involved in cell proliferation (19–21).

Abnormalities of G protein signaling pathways

It has long been known that proteins involved in signaling pathways are possible targets for mutations. As previously demonstrated for nuclear hormone receptors and growth factor receptors, it has been proposed that components of G protein signaling pathways may potentially be involved in the development of neoplastic and non-neoplastic human diseases (1–6, 22, 23). In fact, it has been demonstrated that mutations in the genes encoding these proteins are responsible for several human diseases presenting with the clinical phenotype of hormone excess or defect. The abnormal transduction may be due to mutations in the genes encoding either G protein-coupled receptors or G proteins or effectors. In Table 2 human diseases due to G protein alterations are summarized. By contrast, mutations of effector molecules seem to occur very infrequently in human diseases. In particular, the presence in invasive pituitary tumors of point mutations of protein kinase C- α , an enzyme known to importantly regulates cell growth and differentiation, has been previously reported, but not confirmed by subsequent screening studies (24, 25). Very recently, a mutation in the regulatory subunit of the protein kinase A gene has been identified in patients affected with Carney complex type 1 (26) suggesting the possible involvement of this kinase in the pathogenesis of sporadic endocrine neoplasms, such as pituitary tumors, that are included in this syndrome.

Table 2 Endocrine diseases resulting from G protein alterations.

Gs α			
Loss of function			
Pseudohypoparathyroidism type Ia	Point mutations, deletions, insertions impairing any Gs α functional domain		Germline
Pseudohypoparathyroidism type Ib	Alterations of GNAS1 locus imprinting probably leading to reduced Gs α expression; uncoupling GNAS1 mutation		Germline
Gain of function			
Pituitary or thyroid adenomas	Point mutation of Arg 201 or Gln 227, inhibition of GTP hydrolysis		Somatic
Leydig cell tumors	Point mutation of Arg 201, inhibition of GTP hydrolysis		Somatic
McCune–Albright syndrome	Point mutation of Arg 201, inhibition of GTP hydrolysis		Somatic
Gain or loss of function			
Testotoxicosis with pseudohypoparathyroidism type Ia	Point mutation of Arg385Ser, acceleration of GDP release and signal activation at 34 °C (testis); inactivation of Gs α at 37 °C (parathyroid)		Germline
Gi2 α			
Gain of function			
Pituitary adenomas	Point mutation of Arg 179 or Gln 205, inhibition of GTP hydrolysis		Somatic
Adrenal cortex and ovary tumors	Point mutation of Arg 179, inhibition of GTP hydrolysis		Somatic

The first indication that alterations in the structure of G proteins could lead to development of disease was suggested by the observation that the *Vibrio cholerae* toxin possesses an ADP-ribosyl transferase activity, the target amino acid for this reaction being Arg 201 in the G α subunit. The ADP ribosylation of this residue and the subsequent blockade of the intrinsic GTP-ase activity induces the constitutive activation of G α , leading to maintained and hormone-independent activation of adenyl cyclase. The constitutive activation of adenyl cyclase in intestinal epithelial cells results in increased secretion of electrolytes into the bowel lumen and the subsequent watery diarrhea. *In vitro* mutagenesis experiments confirmed that Arg 201 is a key component of the regulatory turn-off mechanism of G α and a similar role is played by Arg residues at equivalent positions in other G protein α subunits. The pathogenetic toxin of *Bordetella pertussis* causes ADP ribosylation of a cystein residue located in the C-terminal tails of G proteins belonging to the G α family, resulting in reduced responsiveness to receptor activation (15).

In the past few years, molecular biological approaches have provided important insights into the pathogenetic role of naturally occurring mutations in G protein genes with consequent altered signal transduction. The phenotypic expression of these mutations depend on several determinants; in particular, mutations may occur as germ-line mutations, affecting every cell in which the gene is expressed vs somatic mutations that lead to focal manifestations of the disease. Moreover, G protein mutations may cause either loss or gain of function, by inactivating or activating signal transduction, leading to the clinical phenotype of hormone defect or excess, respectively.

Inactivating mutations of the G α gene (GNAS1)

Albright hereditary osteodystrophy and pseudohypoparathyroidism

In 1942 Albright *et al.* described the first hormone resistance syndrome, which they termed pseudohypoparathyroidism (PHP) (27). They reported patients with normal renal function, in which hypocalcemia and hyperphosphatemia were associated with elevation of serum PTH levels. These patients also showed a reduced calcemic and phosphaturic response to injected bovine parathyroid extract compared with patients with primary hypoparathyroidism, leading to the hypothesis of a resistance to PTH action. Moreover, these patients displayed a constellation of physical features including short stature, centripetal obesity, rounded face, short neck and brachydactyly which is now referred to as Albright hereditary osteodystrophy (AHO). In subsequent reports subcutaneous ossifications and mental

retardation were also found to accompany the majority of cases of AHO (28, 29). In contrast, patients showing the physical features of AHO without any evidence of PTH resistance were described by Albright *et al.* ten years after their first report of PHP (30). This new syndrome, which was termed pseudopseudohypoparathyroidism (PPHP) may be present either in kindreds in which PHP is present or as an isolated defect. As more and more cases were described it appeared that the majority of familial PHPs were inherited in an autosomal dominant manner (31–33).

The identification of the PTH receptor and its signal transduction pathway (35, 36) has lead us to a better understanding of PHP pathophysiology. Since the PTH receptor is coupled to Gs and therefore activates cAMP formation, measurement of serum and urinary cAMP levels after the injection of bovine PTH permitted the differentiation of PHP type I, in which a blunted cAMP response is observed, from PHP type II in which the cAMP response to PTH is conserved but a deficient phosphaturic response indicates a defect distal to cAMP generation in target cells (Table 3). Moreover, PHP type I now refers to a heterogeneous group of disorders with AHO clinical manifestations that can be differentiated by the presence (PHP Ia and PHP Ic) (37–41) or absence (PHP Ib) (39, 42) of resistance to hormones other than PTH that act via Gs coupled receptors, such as TSH and gonadotropins. Patients with PHP Ia have a partial deficiency (about 50%) of Gs activity in the membranes of various cell types (erythrocytes, fibroblasts, platelets, etc.), due to a reduction in mRNA and protein levels (38–40) whereas this defect is absent in patients with PHP Ic (42–44) (Table 3). Patients with PPHP generally coexist with PHP Ia in the same family (43) and have the same ~50% deficiency of Gs activity in cell membranes (44, 45). However, in contrast to their relatives with PHP Ia, patients with PPHP show a normal response of urinary cAMP to exogenous PTH (44). Clinical features of PPHP can also be found in families in which PHP Ia is absent, thus presenting as an isolated defect. In these cases diagnosis of PPHP is particularly difficult as many features of AHO are quite unspecific or are present in other disorders, some of which ascribed to specific chromosomal defects, as for the small terminal deletions on chromosome 2 in AHO-like syndrome (46–48).

Table 3 Classification of pseudohypoparathyroidism.

	AHO	Hormone resistance	GNAS1 defect
PHP Ia	Yes	Multiple	Yes
PPHP	Yes	None	Yes
PHP Ib	No	PTH	Yes
PHP Ic	Yes	Multiple	No
PHP II	No	PTH	No

PHP, pseudohypoparathyroidism; PPHP, pseudopseudohypoparathyroidism.

Genetic analysis of GNAS1 gene

PHP type Ia and PPHP

In 1990 Pattern *et al.* (49) detected and described the first heterozygous inactivating mutation in the gene encoding the Gs α (GNAS1), responsible for PHP type Ia in one family. The genetic defect in the majority of patients with PHP Ia and in their relatives with PPHP has been then confirmed by the identification of multiple heterozygous loss of function mutations within this gene (50–65).

The human GNAS1 gene maps to 20q13 (66) and contains 13 exons, its cDNA spanning a region of about 1.2 kb. Figure 2 shows the functional domains encoded by the gene. Mutations have been localized in the entire coding region of the gene, each mutation being usually associated to a single kindred. All exons can be affected by loss of function alterations, with the exception of exon 3, where no mutations have been detected to date. This is not surprising given the alternative splicing patterns observed and the lack of conservation with other α subunits, suggesting that mutations within exon 3 might have little or no clinical consequence. On the other hand, mutations in exon 1 are probably underestimated in the literature, as the extremely GC-rich nature of the flanking sequences has precluded its analysis by many authors. Considering the type of mutations, small insertions/deletions and amino acid substitutions predominate, but nonsense mutations and point mutations that lead to altered translation initiation or aberrant mRNA splicing have also been documented.

An intriguing missense mutation (54, 67) localized within the highly conserved G5 region of the Gs α , has been identified in two unrelated males who presented with AHO, PTH resistance and testotoxicosis (54). This substitution (A366S) leads to constitutive activation of adenylyl cyclase by causing accelerated release of GDP, thus increasing the fraction of active GTP-bound Gs α . However, while this mutant protein is stable at the reduced temperature of the testis, it is thermolabile at 37 °C, resulting in reduced Gs α activity in almost tissues and AHO phenotype. In females, where it has

never been detected, it would be expected to only give rise to AHO.

Although each mutation is usually associated to a single kindred, a mutational hot-spot involving 20% of all mutations so far described has been identified within exon 7 (51, 63–65, 68, 69). It is a 4 bp deletion which coincides with a defined consensus sequence for arrest of DNA polymerase α , a region known to be prone to sporadic deletion mutations (69, 70). In most cases it has been found as a *de novo* mutation, thus representing a recurring new mutation rather than a founder effect. Moreover, four families have been found to carry mutations within exon 5, affecting prolines 115 and 116 (58, 63–65), while three different insertion/deletions have been found to be clustered at nucleotides 1106–1108 in exon 13 (65). Alterations in exon 5 are predicted to disrupt the highly conserved domain of Gs α that interacts with adenylyl cyclase, while exon 13 is responsible for the interaction with the receptor (71). Given the relatively small number of kindreds with PHP Ia described in the literature (about 60), these particular regions seem to undergo mutational changes with a significant frequency, probably representing two new potential mutational hot-spots in GNAS1.

In families in which PHP Ia and PPHP coexist, mutations in GNAS1 can be detected in all the affected members, i.e. members affected with either PHP Ia or PPHP. On the contrary, no mutation in the GNAS1 coding sequence has ever been found in families in whom sporadic or familial PPHP was the only clinical manifestation (48, 63, 64). These results support the view that PHP Ia and isolated PPHP may represent two genetically distinct entities, even if the possibility that a defect may exist in the promoter region or in other regulatory intronic sequences of GNAS1 cannot be completely excluded.

PHP Ib

PHP Ib refers to a condition characterized by renal resistance to PTH in the absence of other endocrine or

Figure 2 Schematic representation of the 13 exons composing the Gs α gene, together with its functional domains (AC: adenylyl cyclase activity domain; GPCR: G-protein coupled receptor interaction domain). Exon 3, which is shaded in the figure, is subjected to alternative splicing. The figure also shows the inactivating (circles) and activating (stars) mutations detected up to now in this gene; the triangle in exon 13 represents an inactivating mutation which has been recently described in a patient with PHP type Ib.

physical abnormalities and in the presence of a normal $Gs\alpha$ activity in cells that can be easily sampled (39, 41, 72, 73). The defect is usually sporadic but occasionally is familial, with a pattern of transmission consistent with an autosomal dominant one (72). The urinary cAMP response to exogenous PTH is blunted (39), implicating a defect in the signaling pathway proximal to cAMP generation. Selective resistance of target tissues to PTH and normal $Gs\alpha$ activity had pointed at mutations in the PTH receptor type 1 gene as possible candidates to explain the disease. However, molecular studies failed to detect genetic alterations in the coding exons and promoter region of the gene, as well as its mRNA (74–76). Moreover, neither in humans nor in mice does inactivation of one PTH1 receptor allele does end in PTH resistance (77, 78).

Linkage analysis has recently (79) mapped the genetic locus for PHP Ib to a small region of chromosome 20q13.3 in four unrelated families. Since *GNAS1* is located in this region, the possibility that some patients with PHP Ib have inherited a *GNAS1* mutation that leads to a selective defect in PTH-dependent signaling has been put forward. Alternatively, another gene very close to *GNAS1* could be responsible for the disease. Both these hypotheses have been confirmed by recent studies. A unique mutation in exon 13 of the *GNAS1* gene, the exon responsible for the interaction with the receptor, that caused autosomal dominant PTH resistance in three brothers with PHP Ib, but which was clinically silent in their mother and maternal grandfather, has been described (79). This mutant $Gs\alpha$ (Δ 11e 382), when expressed *in vitro*, was unable to couple to the PTH 1b receptor but was able to interact normally with other Gs-coupled receptors such as LH, TSH and β -adrenergic receptors, thus explaining the phenotype of the patients. However, the prevalence of *GNAS1* mutations as a cause of PHP Ib is unlikely to be high, since screening studies on several families with this disorder failed to find mutations in the coding sequence of this gene (81).

Another pathogenetic mechanism as a cause of PHP Ib has been proposed by Liu *et al.* (82). They identified a region upstream of the $Gs\alpha$ promoter, which is normally methylated on the maternal allele and unmethylated on the paternal allele (see below), which was unmethylated on both alleles in all 13 patients with PHP Ib studied. Unmethylation allows an alternative exon 1 (exon 1A), normally expressed only from the paternal allele, to be expressed biallelically in PHP Ib patients. Therefore, PHP Ib would be associated with an abnormal expression of exon 1A, leading to a decreased $Gs\alpha$ expression in renal proximal tubules, that normally express $Gs\alpha$ only from the maternal allele. Little or no effect is seen in other tissues, where $Gs\alpha$ is expressed from both parental alleles. How an alteration in the imprinting of exon 1A could alter the expression of *GNAS1* remains to be explained.

PHP Ic

This term refers to a small subset of patients with all the clinical and biochemical features of PHP Ia (generalized hormone resistance and AHO), without evidence of reduced $Gs\alpha$ activity (38–39). The molecular defect responsible for this disease, that may involve any component of the proximal cAMP pathway (adenylyl cyclase, G_i , phosphodiesterases), has not been established yet.

PHP II

Patients affected with PHP II show clinical evidence of PTH resistance with a normal urinary cAMP response to the injection of exogenous PTH but a blunted phosphaturic response to the same hormone (83), thus indicating a defect distal to cAMP production in the PTH-mediated transduction pathway. To date, there is no evidence of the specific alterations responsible for this disorder.

It has also been hypothesized that in most cases PHP II may be an acquired defect secondary to vitamin D deficiency (84), as suggested by the observation that calcium and vitamin D replacement is able to normalize the phosphaturic response to PTH in these patients (81, 84).

GNAS1 and imprinting

Two questions arise when studying families whose members are affected by PHP Ia and PPHP. Firstly, why apparently identical $Gs\alpha$ deficiency associated to the same *GNAS1* mutation can lead to variable phenotypic expression, in particular in terms of presence or absence of generalized hormone resistance in PHP Ia and PPHP, respectively. Secondly, why PHP Ia patients display a resistance to some (PTH, TSH and gonadotropins) but not all hormones that activate the Gs-coupled pathway.

Genomic imprinting of the *GNAS1* gene has been proposed as a potential mechanism to explain the occurrence of PHP Ia and PPHP in patients with *GNAS1* mutations since it is now clear that, with one exception (85), only maternal transmission of *GNAS1* mutations leads to the complete expression of the disease (PHP Ia), while paternal transmission of the same mutations is associated with PPHP in the offspring (86, 87). Moreover, genomic imprinting would be limited mainly to tissues in which there is a parent-of-origin specific difference in hormone responsiveness, such as the renal proximal tubule and the thyroid. Genomic imprinting is an epigenetic phenomenon affecting a small number of genes by which one allele (maternal or paternal) undergoes, either during the embryogenesis or in the post-natal period, a partial or total loss of expression (88). DNA methylation is the critical phenomenon for both the initiation and the

maintenance of imprinting and virtually all imprinted genes known to date have regions in which CpG dinucleotides are differentially methylated between the paternal and maternal alleles. Through the creation of uniparental disomies and partial disomies (89) at least 11 imprinted regions in the mouse genome have been identified. Indeed, *GNAS1* in the mouse (*Gnas1*) maps within a region on distal chromosome 2 presumed to have more than one imprinted gene, as indicated by the distinct and opposite phenotypes resulting from maternal and paternal uniparental disomies of this region (90). Generation of mice with a null allele of *Gnas1* (91) gave strength to this hypothesis. In fact, while homozygous $G\alpha$ deficiency is embryonically lethal, heterozygotes with maternal ($m-/+$) or paternal ($+/p-$) inheritance of the *Gnas1* null allele have distinct phenotypes: $m-/+$, but not $+/p-$, show resistance to PTH, while both have a normal maximal physiological response to vasopressin. Moreover, $G\alpha$ expression studies demonstrated a reduced expression in the renal cortex, but not in the renal inner medulla (site of action of vasopressin) in $m-/+$ mice, as expected on the basis of clinical observations in PHP Ia. More recently, a study demonstrated the exclusive maternal expression of this gene in the renal proximal tubule, but not in other segments of the nephron (92). Interestingly, expression studies gave evidence of paternal imprinting also in brown and white adipose tissue, suggesting that the obesity observed in $m-/+$ mice, as well as in humans with AHO, may be the consequence of markedly reduced $G\alpha$ expression in adipose tissue. Moreover, $m-/+$ newborns have wide, square-shaped bodies, subcutaneous edema and higher birth weights; at 6–21 days after birth, most of these mice develop ataxia, tremor imbalance and difficulties in breathing, probably due to a delayed development of the cerebellar cortex, and then die. Surprisingly, $+/p-$

mice also show an abnormal phenotype, characterized by lower birth weight and decreased fat mass, failure to suckle milk, severe hypoglycemia resulting in early lethality (93).

These observations provide evidence that the variable and tissue-specific hormone resistance observed in PHP Ia may result from tissue-specific imprinting of the *GNAS1* gene, although the $G\alpha$ knockout model is only in part an analogue of the human AHO phenotype. In addition, even if the inheritance pattern of AHO is consistent with imprinting of the *GNAS1* paternal allele, expression studies on RNA from various human fetal tissues have failed to demonstrate monoallelic expression of this gene (94). However, these negative results obtained in fetal tissues may at least in part be due to the fact that imprinting of the paternal allele might be a process beginning and evolving in post-natal life (87). This is in line with the recent observation that $G\alpha$ is monoallelically expressed in human normal pituitary (95).

Recent studies on the *GNAS1* locus indicate that this region is extremely complex, with multiple alternatively spliced transcripts encoding multiple protein products in man as well as in mouse (Fig. 3). By using alternative promoters and first exons, the *GNAS1* locus gives rise not only to the $G\alpha$ gene, but to at least three other gene products, i.e. XL α s (extra large α -like protein), a Golgi-specific isoform of $G\alpha$, and NESP55 (neuroendocrine secretory protein 55), that are oppositely imprinted (96, 97). While the former is expressed from the paternal allele, with its promoter methylated on the maternal one, the latter is expressed from the maternal allele, its promoter being methylated on the paternal one. Both proteins have been found primarily expressed in neuroendocrine tissues and their function is largely unknown (100, 101). A third alternative promoter and first exon (exon 1A) is located

Figure 3 Genomic organization of human *GNAS1* locus. The figure shows four alternative first exons which splice into exon 2, generating four different transcripts: $G\alpha$, NESP55, XL α s and an unknown gene product from exon 1A. Exons 2–13 are common to all transcripts, even if they are not translated in NESP55. The shaded box indicates also the different expression of transcripts in maternal rather than paternal allele (arrows stay for presence of transcription). Finally, an antisense transcript has been recently described and demonstrated to be imprinted in the maternal allele, thus being expressed only in the paternal one.

2.5 kb upstream of $Gs\alpha$ exon 1 and probably generates untranslated transcripts of unknown function with a pattern of expression similar to that of $Gs\alpha$ (101–103). In the mouse, differential methylation in this region is established during gametogenesis, being present in oocytes and absent in spermatozoa and it is then maintained throughout pre- and postimplantation development, thus constituting a methylation imprint mark, which may possibly be important for the tissue-specific imprinting of $Gs\alpha$, whose promoter is, on the contrary, unmethylated (104). Finally, the maternally methylated region upstream of the $Xl\alpha s$ exon gives rise to a spliced poly-adenylated antisense transcript, which spans the upstream NESP55 region (105). This antisense transcript is imprinted and expressed only from the paternal allele, thus suggesting that it may have a specific role in suppressing *in cis* the activity of the paternal NESP55, as it has been already described for other imprinted loci, such as the murine *Igf2r* locus (106).

In conclusion, the organization and regulation of the *GNAS1* locus, as well as the clinical significance of the

different transcripts originating from it, are still insufficiently understood and specifically targeted knockout mice lacking one or more of these alternative first exons will help to solve some of these questions.

Activating mutations of G proteins

Mutations of the *Gsα* gene (*GNAS1*): *gsp* oncogene

The first clue to the possible existence of activating mutations of G protein genes as a cause of human neoplasia arose from the identification of a subset of GH-secreting pituitary adenomas characterized by high levels of *in vitro* GH release, intracellular cAMP accumulation and membrane adenylyl cyclase activity (107). The presence of *GNAS1* mutations leading to the constitutive activation of $Gs\alpha$ was hypothesized on the basis of high adenylyl cyclase levels in basal conditions which were not further stimulated either by agents known to directly activate $Gs\alpha$ such as GTP and

Figure 4 Schematic representation of *gsp* oncogene. Somatic mutations of *GNAS1* gene replacing either Arg 201 with Cys or His or Ser, or Gln 227 with Arg or Leu have been identified in a subset of endocrine tumors. By inhibiting the intrinsic GTPase activity, these mutations cause constitutive activation of adenylyl cyclase (AC), leading to increased cAMP formation and protein kinase A activation. The protein kinase A (PKA) induced phosphorylation of the cAMP responsive element binding protein CREB facilitates its translocation to the nucleus and activation of cAMP-responsive gene transcription.

fluoride, or by peptides operating through Gs-coupled receptors, such as GHRH (107). The subsequent analysis of DNA from these tumors revealed amino acid substitutions in exons 8 and 9, replacing either Arg 201 with Cys, His or Ser, or Gln 227 with Arg or Leu (108–110) (Fig. 4). Although *in vitro* mutagenesis studies have documented a number of possible activating substitutions in GNAS1 gene, these two residues are the only location for mutations so far identified. When transfected into S49 cyc-cells, mutant Gs α showed a 30-fold decrease in intrinsic GTPase activity. Indeed both residues are known to be important in GTP hydrolysis (108). Arg 201 is the residue that is ADP-ribosylated by cholera toxin, this covalent modification resulting in hormone-independent activation of adenylyl cyclase due to GTPase inhibition. Similarly, *in vitro* mutagenesis experiments confirmed that the Gln 227 residue is involved GTP hydrolysis. Therefore, these two mutations cause constitutive activation of cAMP formation by inhibiting the turn-off mechanism of Gs α . Since somatotrophs belong to a set of cells that recognizes cAMP as a mitogenic signal, Gs α may be considered the product of a proto-oncogene that is converted into an oncogene, designated *gsp* (for Gs protein) in selected cell types.

Functional studies of *gsp* oncogene

Studies on cell lines transfected with mutant Gs α yielded important insights into the series of events resulting from the activation of cAMP cascade. Indeed, at variance with the phenotype induced by the activation of the classical oncogenes, the specific pathways activated by cAMP stimulate both growth and specialized functions. Indeed, the transcription of a variety of common cAMP-responsive genes, including the immediate early genes such as *c-fos*, *c-jun* and *jun B*, are enhanced by the expression of mutant Gs α (111). Moreover, mutant Gs α stimulates GH and PRL promoter activity in GH3 cells expressing this protein (112). As far as the mitogenic effect of *gsp* mutations is concerned, the introduction of mutant Gs α results in enhanced function and growth of selected cell types in which the cAMP cascade activates proliferation processes. In particular, Swiss 3T3 fibroblasts carrying mutant Gs α show a mitogenic activity higher than that of wild-type cells, as indicated by the low serum concentration required for growth (113). The introduction of the Gln227Leu mutation in FRTL-5 thyroid cells is sufficient to induce a TSH-independent proliferation (114). Similarly GH3 cells expressing this mutation show enhanced proliferation and GH and PRL secretion (115). Although these results suggest that the expression of mutationally activated Gs α is sufficient to bypass the requirement for the specific growth factor and promotes autonomous cell growth of specific cell types, most of these effects were observed only when cAMP hydrolysis was blocked by phosphodiesterase (PDE)

inhibitors (113, 114). Indeed, the presence of mutant Gs α is accompanied by a concomitant increase in PDE activity and expression, likely as a result of the feedback mechanism by which cAMP controls the expression of its own degrading enzymes (113, 114, 116, 117). The impact of cAMP hydrolysis on the phenotype produced by the expression of mutant Gs α is indicated by the observation that phosphodiesterase blockade results in a further stimulation of both cAMP levels and proliferation in different cell systems (116–118).

gsp Oncogene in pituitary adenomas

Several screening studies confirmed that approximately 30–40% of GH-secreting adenomas is associated with *gsp* mutations, that most frequently replace Arg 201 (wild-type codon TGC) with Cys (mutant codon TGT). Some ethnic differences in the occurrence of these mutations seem to exist due to the considerably low prevalence (5–10%) reported in Japanese acromegalic patients (119–123). The presence of Gs α mutations is not exclusive to GH-secreting adenomas, although its frequency in the other pituitary adenomas is definitely low. Indeed, the *gsp* oncogene has been observed in 0–13% of non-functioning pituitary adenomas (124, 125) while a single study reports its presence in 5% of ACTH-secreting adenomas (126). These mutations are somatic in origin as indicated by the presence of wild-type Gs α in the peripheral blood leukocytes from affected patients and dominant, as indicated by the presence of both mutant and wild-type Gs α in genomic DNA from the tumor.

Several *in vivo* studies indicate no difference in age, sex, clinical features, duration of the disease or cure rate in patients with or without *gsp* mutations (119–121, 123, 127). However, tumors expressing *gsp* mutations are most frequently very small in size, consistent with the hypersecretory activity of tumoral somatotrophs. Due to the constitutive activation of cAMP formation, patients with *gsp*-positive tumors do not increase plasma GH levels after GHRH whereas they respond to agents acting via a cAMP-independent pathway. Moreover, these patients show a high sensitivity to the inhibitory action of long-acting somatostatin analogues, an effect not associated with increased expression of somatostatin receptor sst2 and sst5 in the tumor (127–129).

Since *gsp* mutations would in principle confer growth advantage, the low growth rate of tumors with these mutations probably reflects the existence of mechanisms able to counteract the activation of the cAMP pathway. Over the last few years, some of these mechanisms have been unveiled. Recent studies demonstrated that, in analogy with the upregulation of PDE in FRTL5 expressing mutant Gs α , in *gsp*-positive tumors PDE activity is about 7-fold higher than that observed in wild-type tissues, this effect being mainly due to the increased expression of cAMP-specific PDE4

a)

b)

Figure 5 Phosphodiesterase hyperactivity and overexpression in GH-secreting tumors with *gsp* oncogene. a) Tumors with *gsp* oncogene (on the right) show significantly higher activity of phosphodiesterases (PDE), particularly the cAMP-specific PDE4 isoform, than tumors without this alteration (on the left). b) By RT-PCR analysis it appears that the increased PDE activity observed in *gsp* positive tumors (+) is mainly due to the induction of cAMP specific PDE4C and PDE4D genes transcription. Therefore, the presence of mutant $Gs\alpha$ is accompanied by a concomitant increase in PDE activity and expression, as a result of the feedback mechanism by which cAMP controls the expression of its own degrading enzymes.

(Fig. 5) (117, 130). Moreover, *gsp*-positive tumors highly express two nuclear transcription factors that are final targets of the cAMP-dependent pathway and are positively regulated by cAMP signaling, i.e. the

cAMP-responsive element binding protein (CREB) and the inducible cAMP early repressor (ICER). The increased expression of the repressor transcription factor ICER, that competes with the binding of CREB to CREs, may inhibit the transcription of several cAMP responsive genes, including CREB itself (131). This counteracting mechanism is consistent with a previous report indicating elevated levels of phosphorylated, hence activated, CREB in GH-secreting adenomas, independently of the presence or absence of *gsp* mutations (132). Finally, although no differences in $Gs\alpha$ mRNA levels have been reported in tumors with or without *gsp* mutations, the mutant protein is present in very low amounts, probably because of the increased rate of degradation of the unstable dissociated α subunit (128, 133; Fig. 6). The recent report that the monoallelic expression of $Gs\alpha$ from the maternal allele found in the normal pituitary (95) is relaxed in somatotroph tumors with and without *gsp* mutations suggests the existence of another mechanism, i.e. loss of *GNAS1* imprinting, able to amplify the cAMP pathway independently of the presence or not of *gsp* mutations.

Figure 6 Representative immunoblotting with antibodies to $Gs\alpha$ in *gsp*-positive and -negative tumors. Tumors with *gsp* oncogene are characterized by a reduced or undetectable expression of $Gs\alpha$ protein. This is probably due to the increased rate of degradation of the unstable dissociated α subunit, since the same reduction is observed when *gsp* negative cells are treated with cholera toxin, an agent known to block GTPase activity and to induce constitutive activation of adenylyl cyclase, by ADP-ribosylating Arg 201 in $Gs\alpha$.

gsp Oncogene in thyroid neoplasms

Following the identification of *gsp* mutations in GH-secreting adenomas, mutations involving the same

two hot-spots in the GNAS1 gene have been identified in hyperfunctioning thyroid adenomas (134). This finding is consistent with the key role of the cAMP pathway in mediating TSH action on both thyroid hormone secretion and thyrocyte proliferation. The frequency of *gsp* mutations in thyroid hot nodules is variable from one series to another, ranging from 5 to 30%, and is definitely lower than that of TSH receptor gene mutations (135, 136). Therefore, the main alterations that constitutively activate the cAMP pathway in thyrocytes are mutations in the TSH receptor while in somatotrophs there are mutations in the Gs α gene. As occurs in GH-secreting adenomas with *gsp* mutations, the phenotype of thyroid adenomas carrying mutant Gs α or TSH receptor is different from that predicted on the basis of *in vitro* models. In fact, it has been observed that in tumors with these mutations the expression of the activated, phosphorylated form of CREB is not increased when compared with that of the paired normal thyroid tissue, but decreased (137). It is likely that the increase in PDE activity and expression that occur in these adenomas may participate in determining the loss of activation of the cAMP dependent signaling (118). Mutant Gs α may also be present with low frequency (<10%) in hypofunctioning thyroid adenomas (cold nodules) as well as in differentiated thyroid adenocarcinomas (138). In particular, *gsp* mutations were detected in a subset of papillary and follicular carcinomas selected on the basis of high adenylyl cyclase activity in basal conditions not further stimulated by TSH (139). No *gsp* mutations have been detected in anaplastic carcinoma. The data collected from the different studies indicate that whereas *gsp* oncogene may be considered as an initiator for a minority of hyperfunctioning thyroid adenomas, its role in thyroid tumorigenesis is much less certain.

***gsp* Oncogene in McCune–Albright syndrome**

The identification of activating mutations in the GNAS1 gene in patients with McCune–Albright syndrome (MAS) has provided clear evidence that the activation of the cAMP pathway is associated with hyperfunction and hyperplasia of cells other than pituicytes and thyrocytes. This syndrome is a sporadic disorder characterized by polyostotic fibrous dysplasia, café-au-lait skin hyperpigmentation and autonomous hyperfunction of several endocrine glands, such as gonads, pituitary, thyroid and adrenal cortex, i.e. glands sensitive to trophic agents acting through the cAMP-dependent pathway. Mutations of the Gs α gene have been detected in all affected subjects and Arg 201 is the only location so far reported. Mutant Gs α is expressed in the affected endocrine organs as well as in tissues not classically involved in MAS, the highest proportion of mutant alleles being found in regions of abnormal proliferation (140, 141). This mosaic distribution is consistent with the hypothesis that this

syndrome is due to a somatic mutation in Gs α gene occurring as an early postzygotic event. Therefore, the time of occurrence of GNAS1 mutations seems to be an important factor in determining the nature of the disease. Due to the ubiquitous expression of Gs α , late occurring mutations cause focal disease such as acromegaly and toxic thyroid adenomas, while when the same mutations occur very early in embryogenesis they cause disorders with widespread manifestations, such as McCune–Albright syndrome (MAS). It is tempting to speculate that activating germ-line mutations of Gs α would be incompatible with life (23).

Recent studies have provided insights into the pathological role of mutant Gs α in non-endocrine organs involved in MAS. It has been shown that melanocytes from the café-au-lait spots of MAS patients have high mRNA levels of tyrosinase gene, probably responsible for alteration in skin pigmentation (142). As far as fibrous dysplasia is concerned, high levels of c-fos expression, presumably a consequence of increased adenylyl cyclase activity, have been detected in bone lesions from all MAS patients studied, consistent with the bone disorders present in transgenic mice overexpressing c-fos proto-oncogene. Moreover, transplantation of skeletal progenitor cells obtained from fibrous dysplastic marrow of patients with MAS into immunocompromised mice caused abnormal ossicle formation, resembling human fibrous dysplasia (143, 144). Interestingly, lesion development required the coexistence of normal cells and cells with a mutant allele, thus reproducing the mosaic distribution of Gs α mutations that characterizes the syndrome. Finally, substitutions at Arg 201 of GNAS1 gene have also been found in isolated fibrous dysplasia occurring outside of the context of typical MAS (144).

***gsp* Oncogene in other endocrine disorders**

Other endocrine organs have been screened for *gsp* mutations since they contain cell types in which cAMP is a positive growth stimulus, such as the endocrine pancreas, the parathyroid, the adrenal gland and the gonads. No Gs α mutation has so far been identified in hyperfunctioning neoplasia from the pancreas, the parathyroid or the adrenal glands, the only exception has been an Arg 201 to Cys substitution in the genomic DNA from nodular adrenal hyperplasia in an infant with Cushing's syndrome (145, 146). By contrast, Arg 201 to Cys changes were found in a significant proportion (4 of 6) of ovarian and testicular stromal Leydig cell tumors, that had caused hormonal hypersecretion resulting in virilization and gynecomastia in female and male patients, respectively (147). As reported for other endocrine neoplasias with *gsp* mutations, there was no evidence of clinical or hormonal differences between patients with *gsp*-positive and -negative tumors (147).

Mutations of the $G_{i2\alpha}$ gene

Taking into account that all G proteins have a common mechanism of binding and hydrolyzing GTP and share highly conserved primary structures in regions corresponding to Arg 201 and Gln 227 of $G_{s\alpha}$, it was predicted that other G proteins would be converted into oncogenes by GTPase-inhibiting mutations. At present, the $G_{s\alpha}$ gene is the only gene that has been identified as a target for activating or inactivating mutations that unequivocally cause endocrine diseases (Table 2). In fact, neither activating nor inactivating mutations of Gq, the G protein involved in the activation of the Ca^{2+} -calmodulin protein kinase C-dependent pathway have been identified yet (148). Conversely, discordant data on mutations of G_{i2} protein are present in the literature. In fact, screening studies of human tumors for mutations of the $G_{i2\alpha}$ gene revealed aminoacids substitutions of Arg 179 (corresponding to the Arg 201 of the $G_{s\alpha}$ gene) to His in ovarian sex cord stromal tumors and adrenal cortex tumors. In particular, the mutant $G_{i2\alpha}$ (*gip 2* oncogene) was detected in two granulosa cell tumors and one thecoma from 10 ovarian tumors. However, this data was not confirmed by subsequent screening studies (149). Similarly, two subsequent studies failed to detect $G_{i2\alpha}$ mutations in adrenal cortex adenomas and carcinomas (150, 151). Finally, a different mutation replacing Gln 205 (corresponding to the Gln 227 of the $G_{s\alpha}$ gene) with Arg was reported in three of 22 non-functioning pituitary adenomas. Interestingly, two of these tumors also had concomitant *gsp* mutations, with a paradoxical result in terms of cAMP generation considering that $G_{s\alpha}$ and $G_{i2\alpha}$ genes have opposing effects on adenylyl cyclase activity (Table 1).

The possible oncogenic potential of the constitutive activation of $G_{i2\alpha}$ gene is difficult to ascertain since $G_{i2\alpha}$ is involved in the activation of multiple and probably not fully understood intracellular pathways. It has been demonstrated that the mutant $G_{i2\alpha}$ (*gip 2* oncogene) induces the constitutive inhibition of adenylyl cyclase and reduction of cytosolic calcium in transfected cells (152). However, the *gip2* oncogene may affect pathways other than the cAMP or the Ca^{2+} -calmodulin cascades. In fact, it has been demonstrated that Gi-coupled receptors are able to activate the MAP kinase pathway (21, 153) and that, in certain cell systems, the expression of constitutively active $G_{i\alpha}$ causes cell transformation (154, 155). The mechanism through which *gip2* induces cell proliferation is probably mediated by MAPK activation (153–155).

G-protein $\beta 3$ variant in essential hypertension

The observation of an increased activity of a Na^+/H^+ exchanger in blood cells of a subgroup of hypertensive patients that was consistent with abnormal signaling

by Gi proteins resulted in the identification of substitution in the gene encoding the G protein $\beta 3$ subunit (GNB3) (156). This substitution causes an aberrant splicing of $\beta 3$ mRNA and production of a small subunit that lacks 41 residues in the middle of the amino acid sequence and is constitutively active. Although the mechanisms by which the small $\beta 3$ increases Gi-dependent hormone responses are uncertain, this variant seems to be present in 53% of patients with hypertension and 44% of normotensive subjects, suggesting that the variant allele substantially increases the risk of hypertension (156). If future studies confirm that the G protein $\beta 3$ variant contributes to the incidence of hypertension, this will have important implications for understanding pathogenesis of the disease and for improving its treatment (157).

Conclusions

It is well established that proteins involved in signal transduction are targets for naturally occurring mutations resulting in human diseases. Admittedly, defects in G proteins almost always result in endocrine disorders, the only exception being inactivating mutations of $G_{t\alpha}$, that mediate rod-cell responses to photons in inherited congenital night blindness (158). Since much evidence indicates that several G proteins are involved in cell growth regulation, it is likely that additional endocrine disorders will be found to be caused by G protein defects. To date, however, *GNAS1* is the only gene encoding a G protein that has been identified as a target for mutations that unequivocally cause endocrine diseases. Indeed, inactivating germ line mutations of this gene cause AHO and pseudohypoparathyroidism while activating somatic mutations lead to the proliferation of endocrine cells in which cAMP is a mitogenic signal. Although in the recent years screening studies have detected the presence of new inactivating or activating mutations of *GNAS1* gene and established their prevalence in the different diseases, several questions arise when studying the genotype–phenotype relationships. In particular, why apparently identical $G_{s\alpha}$ deficiency associated with the same *GNAS1* mutation can lead to the presence or absence of generalized hormone resistance, and why the resistance is limited to some hormones, i.e. PTH, TSH and gonadotropins, while others that equally activate the Gs-coupled pathway are unaffected. Although evidence suggests that the variable and tissue-specific hormone resistance observed in PHP Ia may result from tissue-specific imprinting of the *GNAS1* gene, the $G_{s\alpha}$ knockout model is only in part analogous to the human AHO phenotype and other studies are needed to understand the molecular basis of this disorder. Activating mutations of *GNAS1* gene would in principle confer growth advantage in the selected cell types in which cAMP acts as a mitogenic signal, and on this basis these mutations were

referred to as *gsp* oncogene. However, studies carried out on several neoplasias carrying this oncogene, i.e. GH-secreting pituitary adenomas, hyperfunctioning thyroid adenomas and Leydig cell tumors, failed to detect differences in the clinical and hormonal phenotypes. Therefore, the low growth rate of tumors with these mutations probably reflects the existence of mechanisms able to counteract the activation of the cAMP pathway, that are still insufficiently understood. Similarly, the prevalence and significance of Gi2 α mutations are still controversial. Moreover, although this review has focused on G α subunits because they have been well studied and harbor known mutations, studies on β/γ subunits should be particularly fruitful, due to the increasing appreciation of the importance of these components in signal transduction. In this respect, it has been reported that patients with essential hypertension frequently have a $\beta 3$ subunit variant which is constitutively active. Although the impact of the short $\beta 3$ on hormone signaling is not known, it has been suggested that this polymorphism may contribute to hypertension. Finally, the identification of naturally occurring mutations of G proteins has already had major implications for understanding the structure and function of these signaling proteins. Unfortunately, the implications of identifying G protein mutations for diagnosis and treatment of endocrine disorders are, as yet, rather limited.

Acknowledgements

The experimental work presented in this article was partially supported by MURST (Rome) and Ricerca Corrente Funds of Ospedale Maggiore IRCCS (Milan).

References

- 1 Spiegel AM, Shenker A & Weinstein LS. Receptor-effector coupling by G proteins: implications for normal and abnormal signal transduction. *Endocrine Reviews* 1992 **13** 536–565.
- 2 Dhanasekaran N, Heasley LE & Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. *Endocrine Reviews* 1995 **16** 259–270.
- 3 Spiegel AM. Mutations in G proteins and G protein-coupled receptors in endocrine disease. *Journal of Clinical Endocrinology and Metabolism* 1996 **81** 2434–2442.
- 4 Farzel A, Bourne HR & Tahor I. The expanding spectrum of G protein diseases. *New England Journal of Medicine* 1999 **340** 1012–1019.
- 5 Spada A, Lania A & Ballare E. G protein abnormalities in pituitary adenomas. *Molecular and Cellular Endocrinology* 1998 **142** 1–14.
- 6 Spada A, Vallar L & Faglia G. G protein oncogene in pituitary tumors. *Trends in Endocrinology and Metabolism* 1992 **3** 355–360.
- 7 Lambright DG, Sondek J, Bohm A, Skiba NP, Hamm HE & Sigler PB. The 2.0 Å crystal structure of a heterotrimeric G protein. *Nature* 1996 **379** 311–319.
- 8 Wittinghofer A. Deciphering the alphabet of G proteins: the structure of the alpha, beta gamma heterotrimer. *Structure* 1996 **4** 357–361.
- 9 Gautman N, Downes GB, Yan K & Kisselev O. The G-protein betagamma complex. *Cell Signaling* 1998 **10** 447–455.
- 10 Watson N, Linder ME, Druey KM, Kehrl JH & Blumer KJ. RGS family members: GTPase-activating proteins for heterotrimeric G-protein α -subunit. *Nature* 1996 **383** 172–175.
- 11 Hunt TW, Fields TA, Casey PJ & Peralta EG. RGS10 is a selective activator of Gai GTPase activity. *Nature* 1996 **383** 175–177.
- 12 Ross EM & Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. *Annual Reviews of Biochemistry* 2000 **69** 795–827.
- 13 Simon MI, Strathmann MP & Gautam N. Diversity of G proteins in signal transduction. *Science* 1991 **252** 802–808.
- 14 Wilkie TM, Gilbert DS, Olsen AS, Chen XN, Amatruda TT, Korenberg JR *et al.* Evolution of the mammalian G protein α subunit multigene family. *Nature Genetics* 1992 **1** 85–91.
- 15 Sprang SR. G protein mechanisms: insight from structural analysis. *Annual Reviews Biochemistry* 1997 **66** 639–678.
- 16 Ford CE, Skiba NP, Bae H, Daaka Y, Reuveny E, Shekter LR *et al.* Molecular basis for interactions of G protein betagamma subunits with effectors. *Science* 1998 **280** 1271–1274.
- 17 Wang WJ & Gilman AG. Type specific regulation of adenylyl cyclase by G protein $\beta\gamma$ subunits. *Science* 1991 **254** 1500–1503.
- 18 Hanoune J, Pouille Y, Tzavara E, Shen I, Lipskaya L, Miyamoto N *et al.* Adenylyl cyclase: structure, regulation and function in an enzyme superfamily. *Molecular and Cellular Endocrinology* 1997 **128** 179–194.
- 19 Dhanasekaran N, Tsim ST, Dermott JM & Onesime D. Regulation of cell proliferation by G proteins. *Oncogene* 1998 **17** 1383–1394.
- 20 Gutkind JS. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. *Oncogene* 1998 **17** 1331–1342.
- 21 Van Biesen T, Luttrell LM, Hawes BE & Lefkowitz RJ. Mitogenic signaling via G protein coupled receptors. *Endocrine Reviews* 1996 **17** 698–714.
- 22 Sharif M, Sasakawa N & Hanley MR. Malignant transformation by G protein-coupled receptors. *Molecular and Cellular Endocrinology* 1994 **100** 115–119.
- 23 Gordeladze JO, Johansen PW, Paulssen RH, Paulssen EJ & Gautvik KM. G proteins-implications for pathophysiology and disease. *European Journal of Endocrinology* 1994 **131** 557–574.
- 24 Alvaro V, Levy L, Dubray C, Roche A, Peillon F, Querat B *et al.* Invasive human pituitary tumors express a point mutated α -protein kinase-C. *Journal of Clinical Endocrinology and Metabolism* 1993 **77** 1125–1129.
- 25 Schiemann U, Assert R, Moskopp D, Geller R, Hengst K, Gullotta F *et al.* Analysis of a protein kinase C- α mutation in human pituitary tumours. *Journal of Endocrinology* 1997 **153** 131–137.
- 26 Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS *et al.* Mutations of the gene encoding the protein kinase A type I- α regulatory subunit in patients with the Carney complex. *Nature Genetics* 2000 **26** 89–92.
- 27 Albright F, Burnett CH, Smith CH & Parson W. Pseudohypoparathyroidism: an example of Seabright-Bantam syndrome. *Endocrinology* 1942 **30** 922–932.
- 28 Eyre WG & Reed WB. Albright hereditary osteodystrophy with cutaneous bone formation. *Archives of Dermatology* 1971 **104** 634–642.
- 29 Farfel Z & Friedman E. Mental deficiency in pseudohypoparathyroidism type I is associated with Ns-protein deficiency. *Annals of Internal Medicine* 1986 **105** 197–199.
- 30 Albright F, Forbes AP & Henneman PH. Pseudopseudohypoparathyroidism. *Transactions of the Association of American Physicians* 1952 **65** 337–350.
- 31 Farfel Z, Brothers VM, Brickman AS, Conte F, Neer R & Bourne HR. Pseudohypoparathyroidism: inheritance of deficient receptor-cyclase coupling activity. *PNAS* 1981 **78** 3098–3102.
- 32 Fitch N. Albright's hereditary osteodystrophy: a Reviews. *American Journal of Medicine Genetics* 1982 **11** 11–29.

- 33 Weinberg AG & Stone RT. Autosomal dominant inheritance in Albright's hereditary osteodystrophy. *Journal of Pediatrics* 1971 **79** 996–999.
- 34 Van Dop C & Bourne HR. Pseudohypoparathyroidism. *Annual Reviews of Medicine* 1983 **34** 259–266.
- 35 Chase LR, Melson GL & Aurbach GD. Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone. *Journal of Clinical Investigation* 1969 **48** 1832–1844.
- 36 Aurbach GD, Marx SJ & Spiegel AM. Parathyroid hormone, calcitonin, and the calciferols. In *Williams Textbook of Endocrinology*, edn 8, pp 1397–1476. Eds JD Wilson & DW Foster. Philadelphia: Saunders, 1992.
- 37 Levine MA, Downs RW Jr, Singer M, Marx SJ, Aurbach GD & Spiegel AM. Deficient activity of guanine nucleotide regulatory protein in erythrocytes from patients with pseudohypoparathyroidism. *Biochemical and Biophysical Research Communications* 1980 **94** 1319–1324.
- 38 Farfel Z, Brickman AS, Kaslow HR, Brothers VM & Bourne HR. Defect of receptor-cyclase coupling protein in pseudohypoparathyroidism. *New England Journal of Medicine* 1980 **303** 237–242.
- 39 Levine MA, Downs RW Jr, Moses AM, Breslau NA, Marx SJ, Lasker RD *et al.* Resistance to multiple hormones in patients with pseudohypoparathyroidism: association with deficient activity of guanine nucleotide regulatory protein. *American Journal of Medicine* 1983 **74** 545–556.
- 40 Radeke HH, Auf'mkolk B, Juppner H, Krohn HP, Keck E & Hesh RD. Multiple pre- and postreceptor defects in pseudohypoparathyroidism (a multicenter study with 24 patients). *Journal of Clinical Endocrinology and Metabolism* 1986 **62** 393–402.
- 41 Barrett D, Breslau NA, Wax MB, Molinoff PB & Downs RW Jr. New form of pseudohypoparathyroidism with abnormal catalytic adenylate cyclase. *American Journal of Physiology* 1989 **257** E277–E283.
- 42 Silve C, Santora A, Breslau NA, Moses A & Spiegel AM. Selective resistance to parathyroid hormone in cultured skin fibroblasts from patients with pseudohypoparathyroidism type Ib. *Journal of Clinical Endocrinology and Metabolism* 1986 **62** 640–644.
- 43 Mann JB, Alterman S & Hills AG. Albright's hereditary osteodystrophy comprising pseudohypoparathyroidism and pseudopseudohypoparathyroidism with a report of two cases representing the complete syndrome occurring in successive generations. *Annals of Internal Medicine* 1962 **56** 315–342.
- 44 Levine MA, Jap TS, Mauseth RS, Downs RW & Spiegel AM. Activity of the stimulatory guanine nucleotide-binding protein is reduced in erythrocytes from patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism: biochemical, endocrine, and genetic analysis of Albright's hereditary osteodystrophy in six kindreds. *Journal of Clinical Endocrinology and Metabolism* 1986 **62** 497–502.
- 45 Fischer JA, Bourne HR, Dambacher MA, Tschopp F, De Meyer R, Devogelaer JP *et al.* Pseudohypoparathyroidism: inheritance and expression of deficient receptor-cyclase coupling protein activity. *Clinical Endocrinology* 1983 **19** 747–754.
- 46 Wilson LC, Leverton K, Luttikhuis ME, Oley CA, Flint J, Wostenhorne J *et al.* Brachydactyly and mental retardation: an Albright's hereditary osteodystrophy-like syndrome localized to 2q37. *American Journal of Human Genetics* 1995 **56** 400–407.
- 47 Phelan MC, Rogers RC, Clarkson KB, Bowyer FP, Levine MA, Estabrooks LL *et al.* Albright's hereditary osteodystrophy and del(2)(q37.3) in four unrelated individuals. *American Journal of Human Genetics* 1995 **58** 1–7.
- 48 Weinstein LS. Albright hereditary osteodystrophy, pseudohypoparathyroidism, and Gs deficiency. In *G Proteins, Receptors, and Disease*, pp 23–56. Ed AM Spiegel. Totowa, New Jersey: Humana Press, 1998.
- 49 Pattern JL, Johns DR, Valle D, Eil C, Gruppuso PA, Steele G *et al.* Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. *New England Journal of Medicine* 1990 **322** 1412–1419.
- 50 Weinstein LS, Gejman PV, Friedman E, Kadowaki T, Collins RM, Gershon ES *et al.* Mutations of the Gs alpha-subunit gene in Albright's hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. *PNAS* 1990 **87** 8287–8290.
- 51 Weinstein LS, Gejman PB, Mazancourt P, American N & Spiegel AM. A heterozygous 4-bp deletion mutation in the Gs alpha gene (GNAS1) in a patient with Albright's hereditary osteodystrophy. *Genomics* 1992 **13** 1319–1321.
- 52 Miric A, Vecchio JD & Levine MA. Heterogeneous mutations in the gene encoding the alpha-subunit of the stimulatory G protein of adenylcyclase in Albright's hereditary osteodystrophy. *Journal of Clinical Endocrinology and Metabolism* 1993 **76** 1560–1568.
- 53 Schuster V, Eschenhagen T, Kruse K, Gierschik P & Kreth HW. Endocrine and molecular biological studies in a German family with Albright's hereditary osteodystrophy. *European Journal of Pediatrics* 1993 **152** 185–189.
- 54 Iiri T, Herzmark P, Nakamoto JM, van-Dop C & Bourne HR. Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. *Nature* 1994 **371** 164–168.
- 55 Luttikhuis ME, Wilson LC, Leonard JV & Trembath RC. Characterization of a de novo 43-bp deletion of the Gs alpha gene (GNAS1) in Albright's hereditary osteodystrophy. *Genomics* 1994 **21** 455–457.
- 56 Schwindinger WE, Miric A, Zimmerman D & Levine MA. A novel Gs alpha mutant in a patient with Albright's hereditary osteodystrophy uncouples cell surface receptors from adenyl cyclase. *Journal of Biological Chemistry* 1994 **269** 25387–25391.
- 57 Wilson LC, Luttikhuis ME, Clayton PT, Fraser WD & Trembath RC. Parental origin of Gs alpha gene mutations in Albright's hereditary osteodystrophy. *Journal of Medicine Genetics* 1994 **31** 835–839.
- 58 Shapira H, Mouallem M, Shapiro MS, Weisman Y & Farfel Z. Pseudohypo-parathyroidism type Ia: two new heterozygous frameshift mutations in exons 5 and 10 of the Gs alpha gene. *Human Genetics* 1996 **97** 73–75.
- 59 Farfel Z, Iiri T, Shapira H, Roitman A, Mouallem M & Bourne HR. Pseudohypo-parathyroidism: a novel mutation in the $\beta\gamma$ -contact region of Gs alpha impairs receptor stimulation. *Journal of Biological Chemistry* 1996 **271** 19653–19655.
- 60 Warner DR, Gejman PB, Collins RM & Weinstein LS. A novel mutation adjacent to the switch III domain of Gs alpha in a patient with pseudohypoparathyroidism. *Molecular Endocrinology* 1997 **11** 1718–1727.
- 61 Yu D, Yu S, Schuster V, Kruse K, Clericuzio CL & Weinstein LS. Identification of two novel deletion mutations within the Gs alpha gene (GNAS1) in Albright's hereditary osteodystrophy. *Journal of Clinical Endocrinology and Metabolism* 1999 **84** 3254–3259.
- 62 Fisher JA, Egert F, Werder E & Born W. An inherited mutation associated with functional deficiency of the α -subunit of the guanine nucleotide-binding protein Gs in pseudo- and pseudopseudohypoparathyroidism. *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 935–938.
- 63 Ahmed SF, Dixon PH, Bonthron DT, Stirling HF, Barr DG, Kelnar CJ *et al.* GNAS1 mutational analysis in pseudohypoparathyroidism. *Clinical Endocrinology* 1998 **49** 525–531.
- 64 Mantovani G, Romoli , Weber G, Brunelli V, De Menis E, Beccio S *et al.* Mutational analysis of GNAS1 in patients with pseudohypoparathyroidism: identification of two novel mutations. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 4243–4248.
- 65 Aldred MA & Trembath RC. Activating and inactivating mutations in the human GNAS1 gene. *Human Mutations* 2000 **16** 183–189.

- 66 Gejman PV, Weinstein LS, Martinez M, Spiegel RM, Cao O, Hsieh WT *et al.* Genetic mapping of the Gs α -subunit gene (GNAS1) to the distal long arm of chromosome 20 using a polymorphism detected by denaturing gradient gel electrophoresis. *Genomics* 1991 **9** 782–783.
- 67 Nakamoto JM, Jones EA, Zimmerman D, Scott MN, Donlan MA & Van Dop C. A missense mutation in the Gs α gene is associated with pseudohypoparathyroidism Ia (PHP Ia) and gonadotropin-independent precocious puberty (GIPP). *Clinical Research* 1993 **41** 40A.
- 68 Yokoyama M, Takeda K, Iyota K, Okbayashi T & Hashimoto K. A 4-bp deletion mutation of Gs alpha gene in a Japanese patient with pseudoparathyroidism. *Journal Endocrinology Investigation* 1996 **19** 236–241.
- 69 Yu SH, Yu D, Hainline BE, Brener JL, Wilson KA, Wilson LC *et al.* A deletion hot-spot in exon 7 of the Gs α gene (GNAS1) in patients with Albright hereditary osteodystrophy. *Human Molecular Genetics* 1995 **4** 2001–2002.
- 70 Krawczak M & Cooper DN. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. *Human Genetics* **86** 425–441.
- 71 Pennington SR. GTP-binding proteins: heterotrimeric G proteins. *Protein Profile* 1994 **1** 172.
- 72 Winter JS & Hughes IA. Familial pseudohypoparathyroidism without somatic anomalies. *Canadian Medical Association Journal* 1986 **123** 26–31.
- 73 Nusynowitz ML, Frame B & Kolb FO. The spectrum of the hypoparathyroid states: a classification based on physiologic principles. *Medicine* 1976 **55** 105–119.
- 74 Schipani E, Weinstein LS, Bergwitz C, Iida-Klein A, Icong XF, Stuermann M *et al.* Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exons of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene. *Journal of Clinical Endocrinology and Metabolism* 1995 **80** 1611–1621.
- 75 Bettoun JD, Minagawa M, Kwan MY, Lee HS, Yasuda T, Hendy GN *et al.* Cloning and characterization of the promoter regions of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene: analysis of deoxyribonucleic acid from normal subjects and patients with pseudohypoparathyroidism. *Journal of Clinical Endocrinology and Metabolism* 1997 **82** 1031–1040.
- 76 Fukumoto S, Suzawa M, Takeuchi Y, Kodama Y, Nakayama K, Ogata E *et al.* Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib. *Journal of Clinical Endocrinology and Metabolism* 1996 **81** 2554–2558.
- 77 Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A *et al.* PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. *Science* 1996 **273** 663–666.
- 78 Jobert AS, Zhang P, Couvineau A, Bonaventure J, Roume J, Le Merrer M *et al.* Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. *Journal of Clinical Investigation* 1998 **102** 34–40.
- 79 Juppner H, Schipani E, Bastepe M, Cole DE, Lawson ML, Mannstadt M *et al.* The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3. *PNAS* 1998 **95** 11798–11803.
- 80 Wu WI, Schwindinger WF, Aparicio LF & Levine MA. Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of Gs α : a cause of pseudohypoparathyroidism type Ib. *Journal of Biological Chemistry* 2001 **276** 165–171.
- 81 Rodriguez HJ, Villareal H Jr, Klahr S & Slatopolsky E. Pseudohypoparathyroidism type II: restoration of normal renal responsiveness to parathyroid hormone by calcium administration. *Journal of Clinical Endocrinology and Metabolism* 1974 **39** 693–701.
- 82 Liu J, Litman D, Rosenberg MJ, Yu S, Biesecker LG & Weinstein LS. A GNAS1 imprinting defect in pseudohypoparathyroidism type Ib. *Journal of Clinical Investigation* 2000 **106** 1167–1174.
- 83 Drezner M, Neelon FA & Lebovitz HE. Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal. *New England Journal of Medicine* 1973 **289** 1056–1060.
- 84 Rao DS, Parfitt AM, Kleerecooper M, Pumo BS & Frame B. Dissociation between the effects of endogenous parathyroid hormone on adenosine 3',5'-monophosphate generation and phosphate reabsorption in hypocalcemia due to vitamin D depletion: an acquired disorder resembling pseudohypoparathyroidism type II. *Journal of Clinical Endocrinology and Metabolism* 1985 **61** 285–290.
- 85 Shuster V, Krss W & Kruse K. Paternal and maternal transmission of pseudohypoparathyroidism type Ia in a family with Albright's hereditary osteodystrophy: no evidence of genomic imprinting. *Journal of Medicine Genetics* 1994 **31** 84.
- 86 Nakamoto JM, Sandstrom AT, Brickman AS, Christenson RA & Van Dop C. Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gs α gene mutation. *American Journal of Medicine Genetics* 1998 **77** 261–267.
- 87 Weinstein LS & Yu S. The role of genomic imprinting of Gs α in the pathogenesis of Albright's hereditary osteodystrophy. *Trends in Endocrinology and Metabolism* 1999 **10** 81–85.
- 88 Bartolomei MS & Tilgham SM. Genomic imprinting in mammals. *Annual Reviews Genetics* 1997 **31** 493–525.
- 89 Cattanaach BM & Beechey CV. Genomic imprinting in the mouse: possible final analysis. In *Genomic Imprinting: Frontiers in Molecular Biology*, vol 18, pp 118–145. Eds W Reik & A Surani. Oxford, NY, Tokyo: IRL Press, Oxford University Press, 1997.
- 90 Cattanaach BM & Kirk M. Differential activity of maternally and paternally derived chromosome regions in mice. *Nature* 1985 **315** 496–498.
- 91 Yu S, Yu D, Lee E, Eckhaus M, Lee R, Corria Z *et al.* Variable and tissue-specific hormone resistance in heterotrimeric Gs protein α -subunit (Gs α) knockout mice is due to tissue-specific imprinting of the Gs α gene. *PNAS* 1998 **95** 8715–8720.
- 92 Weinstein LS, Yu S & Ecelbarger CA. Variable imprinting of the heterotrimeric G protein Gs α -subunit within different segments of the nephron. *American Journal of Physiology* 2000 **278** F507–F514.
- 93 Yu S, Gavrilova O, Chen H, Lee R, Liu J, Pacak K *et al.* Paternal versus maternal transmission of a stimulatory G-protein α subunit knockout produces opposite effects on energy metabolism. *Journal of Clinical Investigation* 2000 **105** 615–623.
- 94 Campbell R, Gosdem CM & Bonthron DT. Parental origin of transcription from the human GNAS1 gene. *Journal of Medicine Genetics* 1994 **31** 607–614.
- 95 Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A *et al.* Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. *Journal of Clinical Investigation* 2001 **107** R31–R36.
- 96 Hayward BE, Kamiya M, Strain L, Moran V, Campbell R, Hayashizaki Y *et al.* The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. *PNAS* 1998 **95** 10038–10043.
- 97 Hayward BE, Moran V, Strain L & Bonthron DT. Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally and biallelically derived proteins. *PNAS* 1998 **95** 15475–15480.
- 98 Peters J, Wroe SE, Wells CA, Miller HJ, Bodle D, Beechey CV *et al.* A cluster of oppositely imprinted transcripts at the *Gnas* locus in the distal imprinting region of mouse chromosome 2. *PNAS* 1999 **96** 3830–3835.
- 99 Kelsey J, Bodle D, Miller HJ, Beechey CV, Coombes C & Peters J. *et al.* Identification of imprinted loci by methylation-sensitive

- representational difference analysis: application to mouse distal chromosome 2. *Genomics* 1999 **62** 129–138.
- 100 Ischia R, Lovisetti-Scamihorn P, Hogue-Angeletti R, Wolkersdorfer M, Winkler H & Fischer-Colbrie R. Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HT_{1B} receptor antagonist activity. *Journal of Biological Chemistry* 1997 **272** 11657–11662.
 - 101 Kehlenbach RH, Matthey J & Huttner WB. XL α s is a new type of G protein. *Nature* 1994 **372** 804–809.
 - 102 Ishikawa Y, Bianchi C, Nadal-Ginard B & Homey CJ. Alternative promoter and 5' exon generate a novel G α mRNA. *Journal of Biological Chemistry* 1990 **265** 8458–8462.
 - 103 Swaroop A, Agarwal N, Gruen JR, Bick D & Weissman SM. Differential expression of novel G α signal transduction protein cDNA species. *Nucleic Acid Research* 1991 **19** 4725–4729.
 - 104 Liu J, Yu S, Litman D, Chen W & Weinstein LS. Identification of a methylation imprint mark within the mouse *Gnas* locus. *Molecular and Cellular Biology* 2000 **20** 5808–5817.
 - 105 Hayward BE & Bonthron DT. An imprinted antisense transcript at the human *GNAS1* locus. *Human Molecular Genetics* 2000 **9** 835–841.
 - 106 Wutz A, Smrzka OW, Schweifer N, Shellander K, Wagner EF & Barlow DP. Imprinted expression of the *Igf2r* gene depends on an intronic CpG island. *Nature* 1997 **389** 745–749.
 - 107 Vallar L, Spada A & Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. *Nature* 1987 **330** 566–567.
 - 108 Landis C, Masters SB, Spada A, Pace AM, Bourne HR & Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylate cyclase in human pituitary tumors. *Nature* 1989 **340** 692–696.
 - 109 Lyons J, Landis CA, Harsh G, Vallar L, Grunwald K, Feichtinger H *et al.* Two G protein oncogenes in human endocrine tumors. *Science* 1990 **249** 655–659.
 - 110 Clementi E, Maggaretti N, Meldolesi J & Taramelli R. A new constitutively activating mutation of the Gs protein α subunit-*gsp* oncogene is found in human pituitary tumours. *Oncogene* 1990 **5** 1059–1061.
 - 111 Gaidon C, Boutillier AL, Monnier D, Mercken L & Loeffler JP. Genomic effects of the putative oncogene *Gas*: chronic transcriptional activation of *c-fos* protooncogene in endocrine cells. *Journal of Biological Chemistry* 1994 **36** 22663–22671.
 - 112 Tian J, Chen JH & Bancroft C. Expression of constitutively active G α subunit in GH3 pituitary cells stimulates prolactin promoter activity. *Journal of Biological Chemistry* 1994 **269** 33–36.
 - 113 Zachary I, Masters SB & Bourne HR. Increased mitogenic responsiveness of Swiss 3T3 cells expressing constitutively active G α . *Biochemical and Biophysical Research Communication* 1990 **168** 1184–1193.
 - 114 Muca C & Vallar L. Expression of mutationally activated G α s stimulates growth and differentiation of thyroid FRTL 5 cells. *Oncogene* 1994 **9** 3647–3653.
 - 115 Ham J, Ivan M, Wynford-Thomas D & Scanlon MF. GH3 expressing constitutively active Gs alpha (Q227L) show enhanced hormone secretion and proliferation. *Molecular and Cellular Endocrinology* 1997 **127** 41–47.
 - 116 Nemoz G, Sette C, Hess M, Muca C, Vallar L & Conti M. Activation of cyclic nucleotide phosphodiesterase in FRTL-5 thyroid cells expressing a constitutively active G α . *Molecular Endocrinology* 1995 **9** 1279–1287.
 - 117 Lania A, Persani L, Ballare E, Mantovani S, Losa M & Spada A. Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 1624–1628.
 - 118 Persani L, Lania A, Alberti L, Romoli R, Mantovani G, Filetti S *et al.* Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 2872–2878.
 - 119 Landis CA, Harsh G, Lyons J, Davis RL, McCormick F & Bourne HR. Clinic characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. *Journal of Clinical Endocrinology and Metabolism* 1990 **71** 1416–1420.
 - 120 Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M *et al.* Clinical, biochemical and morphological correlates in patients bearing growth hormone secreting tumors with or without constitutively active adenylate cyclase. *Journal of Clinical Endocrinology and Metabolism* 1990 **71** 1421–1426.
 - 121 Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M & Fahlbusch R. Clinical and biochemical characteristics of acromegalic patients harboring *gsp*-positive and *gsp*-negative pituitary tumors. *Neurosurgery* 1993 **33** 198–203.
 - 122 Hosoi E, Yokogoshi Y, Hosoi E, Horie H, Sano T, Yamada S *et al.* Analysis of the G α gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-directed sequencing method using paraffin-embedded tissues. *Acta Endocrinologica* 1993 **129** 301–306.
 - 123 Yang I, Park S, Ryu M, Woo J, Kim S, Kim J *et al.* Characteristics of *gsp* positive growth hormone secreting pituitary tumors in Korean acromegalic patients. *European Journal of Endocrinology* **134** 720–726.
 - 124 Tordjman K, Stern N, Ouaknine G, Yossiphov Y, Razon N, Nordenskjold M *et al.* Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors. *Journal of Clinical Endocrinology and Metabolism* 1993 **77** 765–769.
 - 125 Williamson EA, Daniels M, Foster S, Kelly WF, Kendall-Taylor P & Harris PE. Gs alpha and Gi2 alpha mutations in clinically non-functioning pituitary tumours. *Clinical Endocrinology* 1994 **41** 815–820.
 - 126 Williamson EA, Ince PG, Harrison D, Kendall-Taylor P & Harris PE. G protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. *European Journal of Clinical Investigation* 1995 **25** 128–131.
 - 127 Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H *et al.* Prognostic and therapeutic consequences of Gs alpha mutations in somatotrophic adenomas. *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 1604–1610.
 - 128 Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P & Enjalbert A. Impact of *gsp* oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotrophic adenomas: involvement in octreotide sensitivity. *Journal of Clinical Endocrinology and Metabolism* 1999 **84** 2759–2765.
 - 129 Corbetta S, Ballare E, Mantovani G, Lania A, Losa M, Di Blasio AM *et al.* Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. *European Journal Clinical Investigation* 2001 **31** 208–214.
 - 130 Persani L, Lania A, Borgato S, Filopanti M, Mantovani G, Conti M *et al.* Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of G α mutations. *Journal of Clinical Endocrinology and Metabolism* 2001 (In Press).
 - 131 Peri A, Conforti B, Baglioni-Peri S, Luciani P, Cioppi F, Buci L *et al.* Expression of cAMP responsive element binding protein and inducible cAMP early repressor genes in growth hormone secreting pituitary adenomas with or without mutations of the G α gene. *Journal of Clinical Endocrinology and Metabolism* 2001 **86** 2111–2117.
 - 132 Bertherat J, Chanson P & Montminy M. The cyclic adenosine 3',5'-monophosphate-responsive factor CREB is constitutively activated in human somatotrophic adenomas. *Molecular Endocrinology* 1995 **9** 777–783.
 - 133 Ballare E, Mantovani S, Lania A, Di Blasio AM, Vallar L & Spada A. Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth

- hormone-secreting tumors. *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 4386–4390.
- 134 O'Sullivan C, Barton CM, Staddon SL, Brown CL & Lemoine NR. Activating point mutations of the *gsp* oncogene in human thyroid adenomas. *Molecular Carcinogenesis* 1991 **4** 345–349.
 - 135 Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G *et al.* Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. *Journal of Clinical Endocrinology and Metabolism* 1997 **82** 2695–2701.
 - 136 Farfel Z, Bourne HR & Iiri T. The expanding spectrum of G protein diseases. *New England Journal of Medicine* 1999 **340** 1012–1020.
 - 137 Brunetti A, Chieffari E, Filetti S & Russo D. The 3',5'-cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. *Endocrinology* 2000 **141** 722–730.
 - 138 Moretti F, Nanni S & Pontecorvi A. Molecular pathogenesis of thyroid nodules and cancer in *Baillieres Best Pract Res Clin Endocrinol Metab* 2000 **14** 517–539.
 - 139 Suarez HG, du Villard JA, Caillou B, Schlumberger M, Parmentier C & Monier R. *gsp* mutations in human thyroid tumours. *Oncogene* 1991 **6** 677–679.
 - 140 Weinstein LS, Shenker A, Gejman P, Marino MJ, Friedman E & Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. *New England Journal of Medicine* 1991 **325** 1688–1695.
 - 141 Schwindinger WF, Francomano CA & Levine MA. Identification of a mutation in the gene encoding the α subunit of the stimulatory G-protein of adenylyl cyclase in McCune-Albright syndrome. *PNAS* 1992 **89** 5152–5156.
 - 142 Kim IS, Kim ER, Nam HJ, Chin MO, Moon YH, Oh MR *et al.* Activating mutation of Gs alpha in McCune-Albright syndrome causes skin pigmentation by tyrosinase gene activation on affected melanocytes. *Hormone Research* 1999 **52** 235–240.
 - 143 Candelieri GA, Glorieux FH, Prud'homme J & St-Arnaud R. Increased expression of the *c-fos* proto-oncogene in bone from patients with fibrous dysplasia. *New England Journal of Medicine* 1995 **332** 1546–1551.
 - 144 Bianco P, Kuznetsov SA, Riminucci M, Fisher LW, Spiegel AM & Robey PG. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. *Journal of Clinical Investigation* 1998 **101** 1737–1744.
 - 145 Yoshimoto K, Iwahana H, Fukuda A, Sano T & Itakura M. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis. *Cancer* 1993 **72** 1386–1393.
 - 146 Boston BA, Mandel S, LaFranchi S & Blizotes M. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. *Journal of Clinical Endocrinology and Metabolism* 1994 **79** 890–893.
 - 147 Villares Frago MCD, Latronico AC, Carvalho FM, Zerbini MCN, Marcondes JAM, Araujo LMB *et al.* Activating mutation of the stimulatory G protein (*gsp*) as a putative cause of ovarian and testicular human stromal leydig cell tumors. *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 2074–2078.
 - 148 Oyesiku NM, Evans CO, Brown MR, Blevins LS, Tindall GT & Parks JS. Pituitary adenomas: screening for G α mutations. *Journal of Clinical Endocrinology and Metabolism* 1997 **82** 4184–4188.
 - 149 Shen Y, Mamers P, Jobling T, Burger GH & Fuller PJ. Absence of the previously reported G protein oncogene (*gip2*) in ovarian granulosa cell tumors. *Journal of Clinical Endocrinology and Metabolism* 1996 **81** 4159–4161.
 - 150 Reincke M, Karl M, Travis W & Chrousos GP. No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms. *Journal of Clinical Endocrinology and Metabolism* 1993 **77** 1419–1422.
 - 151 Demeure MJ, Doffek KM, Komorowski RA & Gorski J. G α 2 codon 179 oncogene mutations: absent in adrenal cortex tumors. *World Journal of Surgery* 1996 **20** 928–933.
 - 152 Wong YH, Federman A, Pace AM, Zachary I, Evans T, Pouyssegur J *et al.* Mutant α subunits of G α 2 inhibit cAMP accumulation. *Nature* 1991 **351** 63–65.
 - 153 Pierce KL, Luttrell ML & Lefkowitz RJ. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. *Oncogene* 2001 **20** 1532–1539.
 - 154 Pace AM, Wong YH & Bourne HR. A mutant α subunit of G α 2 induces neoplastic transformation in RAT-1 cells. *PNAS* 1991 **88** 7031–7035.
 - 155 Gupta SK, Gallego C, Lowndes JM, Pleiman CM, Sable C, Eisfelder BJ *et al.* Analysis of the fibroblast transformation potential of GTPase deficient *gip2* oncogenes. *Molecular and Cellular Biology* 1992 **12** 190–197.
 - 156 Siffert W, Roskopf D, Siffert G, Busch S, Moritz A, Erbel R *et al.* Association of a human G protein β 3 subunit variant with hypertension. *Nature Genetics* 1998 **18** 45–48.
 - 157 Iiri T & Bourne HR. G proteins propel surprise. *Nature Genetics* 1998 **18** 8–10.
 - 158 Dryja TP, Hahn LB, Reboul T, Arnaud B. Missense mutation of the gene encoding the α subunit of rod transducin in the Nougaret form of congenital stationary night blindness. *Nature Genetics* 1996 **13** 358–360.

Received 19 April 2001

Accepted 20 June 2001